Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography Of Fibrosis And Cirrhosis

Fatty liver is a condition in which fat builds up in liver. it is very common health issue.it is major public health problems in the world. there is particular concern because fatty liver causes mortality among patients. The incidence and prevalence of disease vary with time. Fibrosis is thickening of connective tissues which is usually as a result of injury and long term inflammation. Cirrhosis is severe scarring of liver which is caused by long term liver damage. The scar tissue replaces healthy tissues which leads to loss of liver function. The Objective of study is to look into radiographic features of fatty liver disease. The high resolution ultrasonography will give more detailed view of disease. The study inclued 150 participants.

Study Overview

• Status: Active, not recruiting
• Conditions: Fibrosis; Cirrhosis
• Intervention / Treatment: Radiation: high resolution ultrasonography

Detailed Description

The other liver conditions like fibrosis and cirrhosis are also examined and correlated with fatty liver disease. The CT and MRI are used to compare with HR ultrasonographic findings. Descriptive statistics and comparative statistics are used to interpret data.

• Study Type: Observational
• Enrollment (Actual): 150

Contacts and Locations

Study Locations

• Pakistan
  • Punjab
    • Sādiqābād, Punjab, Pakistan
      • AL-NAWAZ HOSPITAL,Tillu Road

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Probability Sample

Study Population

to compare the Radiological Spectrum Of Fatty Liver Correlate With High Resolution Ultrasonography (CT, MRI) Of Fibrosis And Cirrhosis

Description

Inclusion Criteria:

• Confirmed diagnosis of fatty liver (steatosis), fibrosis, or cirrhosis.
• Patient consent to undergo imaging and participate in the study.

Exclusion Criteria:

• Other Liver Diseases: Exclusion of patients with other significant liver conditions (e.g., viral hepatitis, autoimmune liver diseases) unless specified.
• Pregnant women may be excluded due to imaging concerns.
• Poor quality or incomplete imaging studies.
• Presence of other severe systemic illnesses that could affect liver function or imaging.
• Recent liver surgeries or invasive procedures that might affect imaging results

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
CT	CT used for the image comparision	12 Months
MRI	CT used for the image comparision	12 Months

Collaborators and Investigators

• Sponsor: Superior University

Study record dates

Study Major Dates

• Study Start (Actual): February 28, 2024
• Primary Completion (Actual): July 1, 2024
• Study Completion (Estimated): March 1, 2025

Study Registration Dates

• First Submitted: December 19, 2024
• First Submitted That Met QC Criteria: December 19, 2024
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: December 19, 2024
• Last Verified: December 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Digestive System Diseases; Liver Diseases; Fibrosis; Fatty Liver; Liver Cirrhosis
• Other Study ID Numbers: MSAHS/Batch-Spring23/038

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No